CAL
TSHA icon

Capital Advisors Ltd’s Taysha Gene Therapies TSHA Stock Holding History

Capital Advisors Ltd’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Hold
79
– – ﹤0.01% 1312
2026
Q1 		$0 Buy
79
+2
+3% +$9 ﹤0.01% 1602
2025
Q4 		$12K Sell
77
-2
-3% -$10 ﹤0.01% 774
2025
Q3 		$0 Hold
79
– – ﹤0.01% 1555
2025
Q2 		$0 Hold
79
– – ﹤0.01% 1628
2025
Q1 		$0 Hold
79
– – ﹤0.01% 1580
2024
Q4 		$0 Hold
79
– – ﹤0.01% 1581
2024
Q3 		$0 Hold
79
– – ﹤0.01% 1610
2024
Q2 		$0 Hold
79
– – ﹤0.01% 1639
2024
Q1 		$0 Hold
79
– – ﹤0.01% 1550
2023
Q4 		$0 Hold
79
– – ﹤0.01% 1489
2023
Q3 		$0 Buy
+79
New +$148 ﹤0.01% 1478

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Advisors Ltd's TSHA Position: Q2 2026 in Review

Capital Advisors Ltd held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 79 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

Capital Advisors Ltd first reported a position in TSHA in Q3 2023 and has held it in 12 quarters since. The position peaked at $12K in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Capital Advisors Ltd held 79 shares of Taysha Gene Therapies worth $1K as of Q2 2026.
  • Capital Advisors Ltd left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1312 holding.
  • Capital Advisors Ltd first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 12 quarters since.
  • Capital Advisors Ltd's Taysha Gene Therapies position peaked at $12K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.